Core Insights - The company achieved significant revenue growth in 2025, driven by the launch of Sephience, a drug for PKU, generating over $111 million in revenue within the first 5.5 months [1] - The company ended 2025 with approximately $1.95 billion in cash, positioning itself well for future commercial and R&D initiatives [2] - Continued strong momentum is expected in the U.S. market, with revenue growth anticipated to be driven by Sephience throughout the year [3]

Company Performance - Auvelity ended the previous year with annualized revenue just above $600 million, marking its third full year since launch in 2022, indicating strong performance in the market [1] - The company is outpacing peers in the industry, reflecting effective marketing strategies and execution [1] Sales Force and Market Access - The sales force has expanded from 160 to 260 in 2024, and further to 300 in 2025, which is expected to enhance market penetration [1] - Current market access coverage stands at 86%, showing improvement over time and contributing to revenue growth [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding its business operations and the status of its New Drug Application for Anaphylm [1] Group 1: Allegations - The lawsuit claims that Aquestive Therapeutics made false or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm [1] - It is alleged that the company concealed the significance of human factors related to the use of its sublingual film, including aspects such as packaging, use, administration, and labeling [1] - Investors reportedly suffered damages when the true details about the company's operations became public [1] Group 2: Class Action Participation - Shareholders who wish to serve as lead plaintiffs must file their motions with the court by May 4, 2026 [1] - A lead plaintiff represents other class members in directing the litigation, but participation is not required to be eligible for recovery [1] - All representation in this case is on a contingency fee basis, meaning shareholders incur no fees or expenses [1] Group 3: About Rosen Law Firm - Rosen Law Firm is recognized for its focus on shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [1] - The firm emphasizes its commitment to improving corporate governance and holding executives accountable for wrongdoing [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing deficiencies [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to insufficient information to justify its eligibility for accelerated approval or priority review [5]. - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated, leading to materially false and misleading public statements [5].

Group 1: Navan, Inc. (NASDAQ:NAVN) - Navan conducted its initial public offering on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share [7] - A class action has been initiated due to allegations that the Offering Documents for the IPO were false and misleading, particularly regarding increased "sales and marketing" expenses [7] - Following the revelation of these issues, Navan's shares declined over 60%, trading as low as $9.01 per share by the time the action commenced [7] Group 2: Corcept Therapeutics Incorporated (NASDAQ:CORT) - Corcept's lead product candidate, relacorilant, is being developed for multiple indications, including hypercortisolism [7] - During the class period, Corcept represented that key clinical trials provided "powerful support" for their New Drug Application (NDA) to the FDA, claiming confidence in the approval process [7] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) regarding the NDA, leading to a stock price drop from $70.20 to $34.80, a decline of 50.4% [7]

Core Viewpoint - A shareholder class action lawsuit has been filed against Corcept Therapeutics, alleging false and misleading statements regarding the clinical trials for its drug relacorilant and the likelihood of approval for its New Drug Application [1]. Group 1: Lawsuit Details - The lawsuit claims that Corcept issued false and misleading statements and failed to disclose material adverse facts related to its clinical trials [1]. - The lawsuit specifically targets shareholders who purchased Corcept's shares between October 31, 2024, and December 30, 2025, and experienced significant losses [2]. Group 2: Legal Representation - Holzer & Holzer, LLC is representing the shareholders in this class action lawsuit and has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct [3]. - The deadline for shareholders to request to be appointed as lead plaintiff in the case is April 21, 2026 [3].

Management View - SIGA Technologies, Inc. continues to focus on supporting global governments in preparedness for biological threats, particularly smallpox, positioning itself as the leading provider of smallpox antiviral treatment to over 30 countries [2] Future Outlook - The company anticipates a decision from the European Medicines Agency (EMA) regarding smallpox in March 2026, indicating ongoing efforts in regulatory approvals and market expansion [2] Global Expansion - SIGA is actively outlining its strategy for the continued global expansion of TPOXX, its antiviral treatment for smallpox, which reflects the company's commitment to addressing public health threats [2]

As filed with the U.S. Securities and Exchange Commission on March 10, 2026. Registration No. 333-291959 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Blue Water Acquisition Corp. IV (203) 489-2110 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Joseph Hernandez 15 E. Putnam Avenue Suite 363 Greenwich, CT 06830 (203) 489-2110 (Exa ...

New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026.SO WHAT: If you purchased Soleno common stock during ...